What is the recommended dosing interval for Mylanta (aluminum hydroxide/magnesium hydroxide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mylanta Dosing Interval

Mylanta (aluminum hydroxide/magnesium hydroxide) should be administered 5-6 times daily after meals and at bedtime, with a maximum of 12 teaspoonfuls (2 teaspoonfuls per dose) in 24 hours. 1

Standard Dosing Regimen

The FDA-approved dosing for aluminum hydroxide-containing antacids like Mylanta is:

  • Dose: 2 teaspoonfuls per administration 1
  • Frequency: 5-6 times daily 1
  • Timing: After meals and at bedtime 1
  • Maximum daily dose: 12 teaspoonfuls in 24 hours 1
  • Duration limitation: Do not use maximum dosage for more than 2 weeks 1

Important Administration Details

  • Shake well before using to ensure proper suspension of active ingredients 1
  • Follow with a sip of water if needed to ensure complete delivery to the stomach 1
  • The frequent dosing interval (every 2-4 hours when awake) is necessary because antacids have a relatively short duration of action 2

Clinical Context and Comparative Effectiveness

Research demonstrates that Mylanta administered every 2 hours provides inferior acid control compared to H2-receptor antagonists. In critically ill patients, Mylanta II given every 2 hours maintained gastric pH above 4 for only 39-61% of the time in different stomach regions, compared to 75-91% with famotidine 2. This highlights the limitation of frequent antacid dosing even at 2-hour intervals.

Common pitfall: The every-2-hour dosing studied in research settings 2, 3 is more frequent than the FDA-labeled 5-6 times daily dosing 1. For routine dyspepsia management, follow the FDA-approved interval; more frequent dosing may be considered in specific clinical scenarios under medical supervision but provides limited additional benefit 2.

The duration of action for aluminum/magnesium hydroxide formulations is approximately 82 minutes in the esophagus and only 26 minutes in the stomach 4, explaining why frequent dosing throughout the day is necessary for sustained symptom relief.

Related Questions

What is the recommended dose of Mylanta (aluminum hydroxide/magnesium hydroxide) for adults?
What is the proper dosage and administration instructions for a PRN (as needed) order for Mylanta (aluminum hydroxide, magnesium hydroxide, and simethicone)?
Is Mylanta (aluminum hydroxide, magnesium hydroxide, simethicone) advised for a 14-year-old?
What is the recommended dosage of Mylanta (aluminum hydroxide, magnesium hydroxide, simethicone) for adults and children over 12 years old?
How do I chart a PRN (as needed) Mylanta (aluminum hydroxide and magnesium hydroxide) order?
What are the diagnostic and treatment implications of a dim CD5+ (Cluster of Differentiation 5) monoclonal B-cell population with immunophenotypic characteristics CD19+ (Cluster of Differentiation 19), CD20+ (Cluster of Differentiation 20), CD5+ (dim), CD23- (Cluster of Differentiation 23), CD38+ (Cluster of Differentiation 38), CD200- (Cluster of Differentiation 200), FMC7+ (Fluorescence Monoclonal Clone 7), lambda-restricted, comprising 15% of total cells?
What is the recommended dose of Mylanta (aluminum hydroxide/magnesium hydroxide) for adults?
What is the diagnosis and management for a dim CD5+ (Cluster of Differentiation 5) monoclonal B-cell population detected in the thyroid, characterized by CD19+ (Cluster of Differentiation 19), CD20+ (Cluster of Differentiation 20), dim CD5+, CD23- (Cluster of Differentiation 23), CD38+ (Cluster of Differentiation 38), CD200- (Cluster of Differentiation 200), FMC7+ (Fluorescence Monoclonal Clone 7), and lambda-restricted light chain expression?
What is the treatment for acute angle closure glaucoma secondary to Topamax (topiramate)?
Does the use of Claritin (loratadine) or Zyrtec (cetirizine) increase the risk of acute angle closure glaucoma in patients taking Topiramate?
What is the management and treatment approach for gastrocolocutaneous fistula (GCCF)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.